Giuseppe Ranieri, Alberto Chiarugi, Daniela Buonvicino
{"title":"Early exposure of NOD/ShiLtJ mice to Freund's adjuvant prompts delayed, spontaneous progressive encephalomyelitis","authors":"Giuseppe Ranieri, Alberto Chiarugi, Daniela Buonvicino","doi":"10.1016/j.jneuroim.2025.578809","DOIUrl":null,"url":null,"abstract":"<div><div>Drugs able to efficiently counteract primary progressive MS (PP-MS) remain an unmet need. The availability of reliable animal models of PP-MS might boost the identification of treatments capable of counteracting disease evolution. Recently, we characterized primary progressive EAE (PP-EAE) in NOD/ShiLtJ mice, showing that it recapitulates several key features of PPMS. However, a fundamental difference between PPMS and PPEAE is that the latter is triggered by loss of tolerance deliberately induced <em>via</em> peripheral expansion of myelin-specific effector T cells (Teff). In the present study, we report that NOD/ShiLtJ mice challenged with complete Freund's adjuvant (CFA) to prevent diabetes onset, developed spontaneous PP-EAE (SPP-EAE). Specifically, we report that the sole CFA challenge induced encephalomyelitis with a similar pattern of that prompted by the complete immunization protocol including CFA, pertussis toxin and MOG<sub>35</sub><sub>–</sub><sub>55</sub>. Mice with SPP-EAE show primary progressive disease evolution, widespread neurodegeneration, and insensitivity to dexamethasone-dependent immunosuppression. Remarkably, however, at variance with the rapid onset of PP-EAE, SPP-EAE manifested after a latency of approximately 4.5 months following CFA injection. This model may represent a valuable experimental tool to study mechanisms underlying spontaneous loss of self-tolerance toward CNS antigens and MS progression, as well as to identify therapies of relevance to treatment of PMS patients.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"410 ","pages":"Article 578809"},"PeriodicalIF":2.5000,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165572825002905","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Drugs able to efficiently counteract primary progressive MS (PP-MS) remain an unmet need. The availability of reliable animal models of PP-MS might boost the identification of treatments capable of counteracting disease evolution. Recently, we characterized primary progressive EAE (PP-EAE) in NOD/ShiLtJ mice, showing that it recapitulates several key features of PPMS. However, a fundamental difference between PPMS and PPEAE is that the latter is triggered by loss of tolerance deliberately induced via peripheral expansion of myelin-specific effector T cells (Teff). In the present study, we report that NOD/ShiLtJ mice challenged with complete Freund's adjuvant (CFA) to prevent diabetes onset, developed spontaneous PP-EAE (SPP-EAE). Specifically, we report that the sole CFA challenge induced encephalomyelitis with a similar pattern of that prompted by the complete immunization protocol including CFA, pertussis toxin and MOG35–55. Mice with SPP-EAE show primary progressive disease evolution, widespread neurodegeneration, and insensitivity to dexamethasone-dependent immunosuppression. Remarkably, however, at variance with the rapid onset of PP-EAE, SPP-EAE manifested after a latency of approximately 4.5 months following CFA injection. This model may represent a valuable experimental tool to study mechanisms underlying spontaneous loss of self-tolerance toward CNS antigens and MS progression, as well as to identify therapies of relevance to treatment of PMS patients.
期刊介绍:
The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.